Evidence map›Paper›PMID 37298615›Full record

ArticleInternational journal of molecular sciences2023

Involvement of the Restoration of Cerebral Blood Flow and Maintenance of eNOS Expression in the Prophylactic Protective Effect of the Novel Ferulic Acid Derivative FAD012 against Ischemia/Reperfusion Injuries in Rats.

Takashi Asano, Meiyan Xuan, Naohiro Iwata, Jun Takayama, Kousuke Hayashi, Yosuke Kato, Toshiya Aoyama, Hiroshi Sugo, Hirokazu Matsuzaki, Bo Yuan and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Takashi AsanoLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.ORCID 0000-0002-5472-5723
Meiyan XuanLaboratory of Organic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Naohiro IwataLaboratory of Immunobiochemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Jun TakayamaLaboratory of Organic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Kousuke HayashiLaboratory of Organic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.ORCID 0009-0007-0212-6909
Yosuke KatoLaboratory of Organic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Toshiya AoyamaLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Hiroshi SugoLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Hirokazu MatsuzakiLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Bo YuanLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.ORCID 0000-0002-3406-258X
Shinya KamiuchiLaboratory of Immunobiochemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Yasuhide HibinoLaboratory of Immunobiochemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Takeshi SakamotoLaboratory of Organic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Mari OkazakiLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Josai University · JP

Funding

Japan Society for the Promotion of Science 16K09255Japan Society for the Promotion of Science 19K07873
6 · The paper itself

Abstract

Tissue plasminogen activator, aiming to restore cerebral blood flow (CBF), has been used for acute ischemic strokes in clinics; however, its narrow therapeutic time window remains a serious concern. To develop novel prophylactic drugs to alleviate cerebral ischemia/reperfusion injuries, ferulic acid derivative 012 (FAD012) was synthesized and showed comparable antioxidant properties to ferulic acid (FA) and probably possesses the potent ability to cross the blood-brain barrier. A more potent cytoprotective effect of FAD012 against H

Indexed as

Brain IschemiaNeuroprotective AgentsReperfusion InjuryAnimalsCerebrovascular CirculationCoumaric AcidsEndothelial CellsHydrogen PeroxideInfarction, Middle Cerebral ArteryNitric Oxide SynthaseRatsRats, Sprague-DawleyTissue Plasminogen ActivatorCoumaric AcidsFAD012ferulic acidHydrogen PeroxideNeuroprotective AgentsNitric Oxide SynthaseTissue Plasminogen Activatorcerebral blood flowendothelial nitrogen oxide synthetaseferulic acid derivativeischemia/reperfusion injurymiddle cerebral artery occlusionoxidative stress

Identifiers

PMID37298615
PMCPMC10253792
OpenAlexW4379230421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.